| Stage | CMCSA | % of rev | GLIBA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $29.3B | 100.00% | $267M | 100.00% | CMCSA ×109.73 |
| Gross profit | $21.8B | 74.35% | $267M | 100.00% | GLIBA +25.7pp |
| Operating income | $5.3B | 18.16% | $36M | 13.48% | CMCSA +4.7pp |
| Pre-tax income | $4.4B | 15.18% | $37M | 13.86% | CMCSA +1.3pp |
| Net income | $3.4B | 11.48% | $27M | 10.11% | CMCSA +1.4pp |
| Stage | CMCSA | GLIBA | Gap · A − B |
|---|---|---|---|
| Revenue | $29.3B100.00% | $267M100.00% | CMCSA ×109.73 |
| Gross profit | 74.35%$21.8B | 100.00%$267M | GLIBA +25.7pp |
| Operating income | 18.16%$5.3B | 13.48%$36M | CMCSA +4.7pp |
| Pre-tax income | 15.18%$4.4B | 13.86%$37M | CMCSA +1.3pp |
| Net income |
| 11.48%$3.4B |
| 10.11%$27M |
| CMCSA +1.4pp |
No disclosed counterparties: GLIBA.
None